image
Healthcare - Biotechnology - NASDAQ - US
$ 40.37
-0.908 %
$ 11 B
Market Cap
18.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 22, 2025.

The intrinsic value of one EXEL stock under the worst case scenario is HIDDEN Compared to the current market price of 40.4 USD, Exelixis, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 22, 2025.

The intrinsic value of one EXEL stock under the base case scenario is HIDDEN Compared to the current market price of 40.4 USD, Exelixis, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 22, 2025.

The intrinsic value of one EXEL stock under the best case scenario is HIDDEN Compared to the current market price of 40.4 USD, Exelixis, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EXEL

image
$48.0$48.0$46.0$46.0$44.0$44.0$42.0$42.0$40.0$40.0$38.0$38.0$36.0$36.0$34.0$34.0$32.0$32.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
2.17 B REVENUE
18.49%
605 M OPERATING INCOME
253.82%
521 M NET INCOME
150.89%
700 M OPERATING CASH FLOW
110.00%
-117 M INVESTING CASH FLOW
-333.25%
-629 M FINANCING CASH FLOW
-15.16%
555 M REVENUE
-2.00%
187 M OPERATING INCOME
14.49%
160 M NET INCOME
14.12%
211 M OPERATING CASH FLOW
-12.00%
49.8 M INVESTING CASH FLOW
153.39%
-295 M FINANCING CASH FLOW
-56.79%
Balance Sheet Exelixis, Inc.
image
Current Assets 1.47 B
Cash & Short-Term Investments 1.11 B
Receivables 265 M
Other Current Assets 90.9 M
Non-Current Assets 1.48 B
Long-Term Investments 637 M
PP&E 359 M
Other Non-Current Assets 484 M
37.70 %9.00 %3.08 %21.62 %12.18 %16.41 %Total Assets$2.9b
Current Liabilities 404 M
Accounts Payable 38.2 M
Short-Term Debt 0
Other Current Liabilities 366 M
Non-Current Liabilities 300 M
Long-Term Debt 191 M
Other Non-Current Liabilities 109 M
5.43 %51.97 %27.13 %15.48 %Total Liabilities$703.5m
EFFICIENCY
Earnings Waterfall Exelixis, Inc.
image
Revenue 2.17 B
Cost Of Revenue 76.2 M
Gross Profit 2.09 B
Operating Expenses 1.49 B
Operating Income 605 M
Other Expenses 83.4 M
Net Income 521 M
3b3b2b2b2b2b1b1b500m500m002b(76m)2b(1b)605m(83m)521mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
96.49% GROSS MARGIN
96.49%
27.88% OPERATING MARGIN
27.88%
24.04% NET MARGIN
24.04%
23.23% ROE
23.23%
17.68% ROA
17.68%
18.18% ROIC
18.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Exelixis, Inc.
image
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 521 M
Depreciation & Amortization 28.8 M
Capital Expenditures -66.2 M
Stock-Based Compensation 93.8 M
Change in Working Capital -13.5 M
Others 129 M
Free Cash Flow 634 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Exelixis, Inc.
image
Wall Street analysts predict an average 1-year price target for EXEL of $33.9 , with forecasts ranging from a low of $18 to a high of $47 .
EXEL Lowest Price Target Wall Street Target
18 USD -55.41%
EXEL Average Price Target Wall Street Target
33.9 USD -16.05%
EXEL Highest Price Target Wall Street Target
47 USD 16.42%
Price
Max Price Target
Min Price Target
Average Price Target
50504545404035353030252520201515Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Exelixis, Inc.
image
Sold
0-3 MONTHS
20.1 M USD 10
3-6 MONTHS
11.1 M USD 10
6-9 MONTHS
11.5 M USD 4
9-12 MONTHS
10.4 M USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for CABOMETYX® (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. businesswire.com - 5 days ago
Here's Why Exelixis (EXEL) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 week ago
EXEL or ARGX: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 1 week ago
4 Attractive GARP Picks for Your Portfolio Based on PEG Ratio Here are four discounted PEG stocks that qualify our screening criteria and could be good picks. These are FLEX, CVS, URBN and EXEL. zacks.com - 1 week ago
Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 week ago
3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL) I like to keep things simple—I look for stocks that have strong price momentum, top Zacks Ranks, reasonable valuations and high growth forecasts. Momentum indicates that the market recognizes a winner, the Zacks rank reflects improving analyst expectations, a reasonable valuation limits downside risk and growth is what ultimately drives stock returns. zacks.com - 2 weeks ago
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market. zacks.com - 2 weeks ago
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 2 weeks ago
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations. zacks.com - 3 weeks ago
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 3 weeks ago
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks Top-ranked stocks Urban Outfitters (URBN), Tenet Healthcare (THC), Five9 (FIVN), Marqeta (MQ) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases. zacks.com - 3 weeks ago
Here's Why Exelixis (EXEL) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 3 weeks ago
8. Profile Summary

Exelixis, Inc. EXEL

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 11 B
Dividend Yield 0.00%
Description Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Contact 1851 Harbor Bay Parkway, Alameda, CA, 94502 https://www.exelixis.com
IPO Date April 17, 2000
Employees 1147
Officers Mr. Christopher J. Senner Executive Vice President & Chief Financial Officer Dr. Dana T. Aftab Ph.D. Executive Vice President of Discovery and Translational Research & Chief Scientific Officer Dr. Amy C. Peterson M.D. Executive Vice President of Product Development & Medical Affairs and Chief Medical Officer Dr. William Berg M.D. Senior Vice President of Medical Affairs Mr. Patrick Joseph Haley M.B.A. Executive Vice President of Commercial Dr. Anne Champsaur M.D. Senior Vice President of Drug Safety Ms. Susan T. Hubbard Executive Vice President of Public Affairs & Investor Relations Mr. Jeffrey J. Hessekiel J.D. Executive Vice President & General Counsel Dr. Michael M. Morrissey Ph.D. Chief Executive Officer, President & Director Dr. Stelios Papadopoulos Ph.D. Co-Founder & Independent Chair of the Board